Individual Study / The Flec-SL trial

The Flec-SL trial

The Flec-SL trial

Initiatives -
A randomized trial to test the hypothesis that short-term pharmacological reversal of electrical remodeling after cardioversion is equally efficient to prevent recurrent atrial fibrillation as standard long-term antiarrhythmic therapy.
Start Year
2005
End Year
2011
Visit The Flec-SL trial

Members

Download
Investigators Contacts
  • Dr. Paulus Kirkchhof
    University of Birmingham

Design

Study design
Patients' cohort

Marker Paper

Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial [published correction appears in Lancet. 2012 Oct 13;380(9850):1308]. Lancet. 2012;380(9838):238-246. doi:10.1016/S0140-6736(12)60570-4

PUBMED 22713626

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
760
Number of participants with biosamples

Access

Availability of data and biosamples

Data
Biosamples
Other